Aliskiren and valsartan in combination is a promising therapy for hypertensive renal injury in rats
Neither ACEI nor ARBs completely repress the RAAS. Aliskiren is a newer agent that inhibits renin. However, it increases the biosynthesis and secretion of renin and prorenin, that might induce renal tissue damage. This study was conducted to investigate the renoprotective effects of aliskiren and va...
Main Author: | Hala Salah Abdel Kawy |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-08-01
|
Series: | Clinical and Experimental Hypertension |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/10641963.2017.1407333 |
Similar Items
-
Aliskiren, Obat Antihipertensi Baru dengan Mekanisme Penghambat Renin
by: Diana Holidah
Published: (2011-12-01) -
COMBINATION OF DIRECT RENNIN INHIBITOR - ALISKIREN, ANGIOTENSIN II RECEPTOR BLOCKER - VALSARTAN, AND CALCIUM CHANNEL BLOCKER - AMLODIPINE, IN THERAPY OF HYPERTENSIVE PATIENT WITH GOUT (CASE REPORT)
by: O. V. Dralova, et al.
Published: (2016-01-01) -
Antidepressant-like Effects of Renin Inhibitor Aliskiren in an Inflammatory Mouse Model of Depression
by: Sami I. Alzarea, et al.
Published: (2022-05-01) -
The results of the open observational, international, multicenter, prospective program to assess the efficacy, safety and tolerability of the first direct renin inhibitor RasilezR (aliskiren) in patients with arterial hypertension in ‘real-life’ clinical practice settings (DRIve)
by: I Ye Chazova
Published: (2014-09-01) -
COVID-19 and RAAS blockers: Could Aliskiren be an appropriate option?
by: Selçuk Şen, et al.
Published: (2020-10-01)